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Abstract
Objective: visual disorders are among the earliest symptoms of Alzheimer’s disease. It is, however, still controversial
as to whether Alzheimer’s disease impairs colour vision. In this study, colour vision of Alzheimer’s disease patients was
tested using the Ishihara test and the PV-16 choice test. The latter test, primarily designed for children, was chosen in
order to avoid problems due to cognitive decline.
Methods: 26 patients with mild to severe Alzheimer’s disease (M:F=5:21; mean age: 80"9 years, range: 53–95 years)
and 25 controls (M:F=5:20; mean age 80"10 years, range: 56–100 years) were rated after undergoing complete
neuro-ophthalmologic examination.
Results: the Alzheimer’s disease patients made significantly more unspecific errors in the Ishihara test (P=0.02) and
in the PV-16 choice test (P=0.0008) than the controls. No relation between test performance and severity of
Alzheimer’s disease was found.
Conclusions: Alzheimer’s disease patients have an unspecific colour vision deficiency independent of the severity of
the disease.
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Introduction
Alzheimer’s disease (AD) is a progressive neurodegen-
erative disease associated with deficits in visual function
including stereopsis, contrast sensitivity, and motion detec-
tion [1]. The question as to whether AD also impairs colour
vision is, however, still controversial. While some studies
did not find a significant difference in colour vision
between AD patients and controls [2–4], others have
described various colour vision deficiencies in AD [5–7].
In general, three colour axes exist: the deutan (green),
the protan (red) and the tritan (blue) axis. Light is per-
ceived by photoreceptors specifically sensitive to one of
the three axes. Some researchers came to the conclusion
that AD patients make more tritan errors than controls
[5, 6], while others found colour distortions in the deutan
axis only [7]. Since the testing methods vary from study
to study, direct comparisons are difficult. Another pro-
blem is that some of the applied colour vision tests might
have been too complicated for patients with AD, leading
to unreliable results. As recent studies indicate that
problems in naming of colours may result from cognitive
decline in AD [7], conventional colour tests should
probably not be applied in AD patients. Therefore, in
this study colour vision of AD patients and controls
was tested with the PV-16 choice test, a test specially
designed for children. The main difference between this
test and those for adults is that it has less intellectual
demand and does not take long to perform, thereby
reducing problems due to cognitive decline. The PV-16
test is specialised for detection of acquired colour vision
deficits in the protan, deutan and tritan axis. In addition,
the more commonly used Ishihara test was employed in a
modified form. If a patient was unable to name numbers
on pseudo-isochromatic plates, he or she was encouraged
to follow the number with a finger. With the Ishihara test,
protan and deutan deficiencies can be detected; however,
deficits in the tritan axis are not recognised.
Methods
Study design
This study was planned as an observational retrospective
cross-sectional study. In order to estimate the necessary
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number of patients we performed a power calculation
based on the following assumptions.
i. Because subjects with known colour vision defi-
ciency would be excluded from the study, we estimated
a proportion of 1% colour vision deficiency in the
control group.
ii. In AD patients we estimated a proportion of 30%
colour vision deficiency.
iii. The power was set to 85% and the level of
significance was set to 0.05.
iv. The number of necessary subjects calculated
according to Altman [8] was 50.
Subjects
Twenty-six institutionalised AD patients (M:F=5:21;
mean age: 80"9 years, range: 53–95 years) in the
Psychiatric University Clinic Basel, Switzerland were
consecutively recruited by one examiner (E.S.). All pati-
ents fulfilled clinical diagnostic criteria for AD according
to ICD-10. If the diagnosis of AD was uncertain or
dementia of different aetiology such as vascular dementia
was apparent in magnetic resonance imaging (MRI),
patients were excluded. According to the results of the
Mini Mental Status Examination (MMSE) [9], subjects
were divided into three groups: mild AD with MMSE
score 30–20 (n=10); moderate AD with MMSE score
19–11 (n=15); and severe AD with MMSE score 10–0
(n=1). The mean MMSE score was 18"5, range 9–25.
Twenty-five controls (M:F=5:20; mean age 80"10
years, range: 56–100 years) were consecutively recruited
by one examiner (H.K.) from patients of the University
Eye Clinic, Basel, Switzerland using minimisation [8] for
absence/prevalence of cataract [8] to ensure balance
between the groups. Controls presented with minor eye
disease not affecting colour vision or for routine exami-
nation. Controls had no history nor symptoms of AD or
any other form of dementia.
Mean MMSE score of the controls was 27"2, range
25–30. As visual acuity of at least 20/200 is required
to perform colour vision tests [10], only subjects who
fulfilled this criterion were included in the study. Subjects
and patients with a history of colour blindness, diseases
with known impact on colour vision (e.g. glaucoma,
progressive cone dystrophy, hereditary dominant optic
atrophy, multiple sclerosis) except cataract and age-
related macular degeneration (AMD), or medication with
known influence on colour vision (e.g. ibuprofen,
indomethacin) were excluded from the study.
In general elderly people suffer more frequently from
cataract and AMD, diseases with potential influence on
colour vision [11–13]. Therefore these diseases were not
considered as exclusion criteria; however, we tried to
adjust the number of cataracts in AD patients (n=15)
and controls (n=14) by minimisation. It is known that
subjects with advanced AMD show an increased risk for
AD [14]. Therefore we refrained from adjustment for
AMD in order to reflect normal conditions in an aged
population. Mild to moderate AMD was present in 5 AD
patients and in 2 controls.
Neuro-ophthalmologic examination
All patients underwent a neuro-ophthalmologic exam-
ination including best corrected visual acuity, pupillary
reaction, random dot test for stereoscopic vision (Lang I
test), motility, saccades, confrontation visual field, slit-
lamp biomicroscopy, and Goldmann applanation tono-
metry. In order to avoid problems due to cognitive
decline, visual acuity was tested using the Lea Hyva¨rinen
(LH) test, a symbolic chart test specially designed for
children. All examinations were performed by one
experienced ophthalmologist (M.P.). Colour vision
testing (Ishihara test, PV-16 choice test, see below)
was performed by a different experienced examiner (C.S.).
Colour vision tests
Ishihara test
The Ishihara test, widely used for screening of deficits
in the protan and deutan axes, consists of 38 pseudo-
isochromatic plates, each with a circle of dots and a number
inside the circle. Test plates are composed in such a way
that subjects with normal vision can recognise the number
in the circle, whereas subjects with colour vision deficits
cannot differentiate between number and background.
When naming of the numbers in the Ishihara test was
too difficult for AD patients, they were allowed to follow
the number with their finger. Results were scored as
pathological when three or more mistakes were made.
PV-16 choice test
The PV-16 choice test is especially suitable for detection
of acquired colour vision deficits in the protan, deutan
and tritan axes. It represents a children’s version of the
Farnsworth-Munsell-100-Hue test. The PV-16 choice
test is unique with respect to other colour vision tests in
that it uses large cap sizes, which give more information
about colour vision function and also improves the
ability of low vision individuals to perform this test.
The test exists in a saturated and desaturated form. The
saturated form is used when strong deficiencies are
expected, while the desaturated form is used when the
deficits are expected to be only small. In order to mini-
mise the influence of cataract, which per se affects mainly
the tritan axis, we chose the saturated form of the PV-16
choice test.
In the PV-16 choice test the ability to arrange colour
caps in a smooth uninterrupted hue sequence, progressing
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from the starting hue, is tested. Errors in the PV-16 test
are plotted on a circular diagram, which is arranged so
that correct ordering of caps results in a standard hue
circle. Major translocation errors in the sequencing of
the caps produce lines that cross the diagram from one
side to the other. Protan, deutan, and tritan-type deficits
are reflected by lines parallel to the respective three refer-
ence lines shown (see Figure 1). Two or more switches in
the colour order were considered pathological.
Statistical analysis
Statistical analysis was performed using the statistical
package StatView 4.5 (Abacus Concepts, Berkley, CA).
Comparisons of significance of difference for indepen-
dent groups were performed using unpaired t-test. The
chi-square statistic (232 table, contingency table) was
used for frequency comparisons (nominal categorised
variables). Significance was calculated using Fisher’s exact
test. Data were expressed as mean"standard error of
the mean and statistical significance was set to P-0.05.
Multiple regression and analysis of covariation was
performed.
Results
Neuro-ophthalmologic examination
Visual acuity. Mean visual acuity was 20/50"20/200 in
AD patients and 20/32"20/100 in controls. The lower
visual acuity in the AD group appeared to be related
primarily to diminished ability to cooperate. To perform
colour vision tests, a visual acuity of at least 20/200 is
required, which was the criterion for inclusion in the
study.
Pupillary reaction. Pupillary reaction was intact in all AD
patients and controls.
Stereopsis. Stereopsis was intact in 56% of the AD patients
and in 80% of the controls. The difference between the
groups, however, was not statistically significant.
Motility. Hypometric saccades were present in 2 AD
patients. In all other subjects, saccadic pursuit was normal.
Confrontation visual field. No gross visual field defects were
detected in either the AD or the control group.
Biomicroscopy. Mild to moderate cataract was present in 15
AD patients and in 14 controls. In both the AD and the
control group, 7 subjects were pseudophakic in both
eyes. One AD patient presented with a tilted disc. Mild
to moderate AMD was present in 5 AD patients and in 2
controls.
Intraocular pressure. Mean intraocular pressure was
significantly lower in AD patients (12.2"1.7) when
compared to controls (15.3"3.3) (P-0.04).
Colour vision tests
Ishihara test
All subjects could recognise the non-pseudo-isochromatic
control plate, thus showing that cognitive impairment
did not influence the results. AD patients made signi-
ficantly more errors than controls (x2=5.8; df=1; P=0.02).
Figure 1. PV-16 test results are plotted on a circular diagram, which is arranged so that correct ordering of caps results in a
standard hue circle, with the blue end of the spectrum at cap No. 1 and the violet end at cap No. 15. Major translocational
errors result in lines that cross the circle from one side to another. Protan, deutan, and tritan-type deficits are reflected by
lines parallel to the respective three reference lines shown. Left side: Normal performance of a control. Minor transpositions
of adjacent caps, as seen here, were not scored as discrimination errors. Right side: Performance of an AD patient showing
unspecific colour-vision deficiency.
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The errors did not occur in a particular axis but remained
unspecific. Only 62% of all AD patients completed the
test without errors, in contrast with 88% of the con-
trols. Considering each test plate separately, AD patients
had more difficulties with recognising plates No. 5, 9,
and 10–15 (see Table 1). No relation between perfor-
mance in the Ishihara test and severity of AD was
found.
PV-16 choice test
Forty-six per cent of AD patients and all controls could
complete the PV-16 test in a reliable way. When pro-
blems in AD patients appeared to be more related to the
understanding of the task itself than to problems in
colour vision, results were not included in the analysis.
Those who completed the test (n=12, 46%) made
significantly more errors than controls (x2=13.0; df=1;
P=0.0008). Whereas 96% of the controls were able to
perform this test without errors, only 42% (n=5) of the
AD patients who completed the test did so without
errors. The errors did not occur in specific axes but
rather were unspecific (see Figure 1). No relation between
performance in the PV-16 choice test and severity of
AD was found.
Discussion
Our results demonstrate that AD patients suffer signi-
ficantly more often from colour vision deficiencies than
controls. Unlike previous studies, which found either no
significant difference between AD patients and controls
[2–4], or else disturbances along specific colour axes [5–
7], the deficiencies found in this study were unspecific.
Different testing methods may account at least in part
for the heterogeneous outcome of the studies listed
above. In the present study, colour vision of AD patients
and controls was tested with a modified version of the
Ishihara test and the PV-16 choice test, a test specially
designed for children and people with poor vision. No
relation between performance of both the Ishihara and
the PV-16 choice tests and the severity of AD was found,
which is in agreement with previous studies [7, 15]. By
contrast, McCleary et al. [16] reported a correlation
between errors in the Ishihara test and MMSE scores.
The latter study suggests that the Ishihara test might
be less suitable for determining whether colour vision
deficiencies exist in AD patients. However, in our study
the Ishihara test was used in such a way that patients who
had difficulties naming the numbers on the pseudo-
isochromatic were encouraged to identify the number
non-verbally. The fact that all patients recognised the
non-isochromatic control plate either by naming or by
following with their finger indicates that performance of
the Ishihara test is not beyond the cognitive abilities of
AD patients. However, while all subjects could complete
the Ishihara test, only 12 of the 26 AD patients were able
to complete the PV-16 test in a reliable way. Even though
the PV-16 choice test was carried out with patience from
the observer side, many AD patients appeared to have
difficulties performing the test. They were unable to
reproduce earlier findings, did not understand the task at
all, or lost interest in the test before it was finished. In
such cases, the test was rated as not assessable rather
than pathological. For further analysis, data were
analysed after correcting for missing values, thus possibly
explaining the different outcome of the present study
and previous studies with a similar design. This low rate
of completion constrains the PV-16 test to AD patients
capable of participating and is therefore not a good
screening tool. But if the patient is able to perform the
task, the PV-16 can detect colour vision deficiencies in all
three axes.
Surprisingly, we also found a difference in visual
acuity. This might be also due to the fact that the assess-
ment of visual acuity seemed to take longer in patients
than in controls. This might have also led to mental
exhaustion of the AD patients before their final acuity
was assessed. The difference in eye pressure is of no
clinical relevance as data of both groups are within the
normal range.
Several lines of evidence suggest that visual dysfunc-
tion in AD patients is related more to neuropathology of
the visual cortex than to changes in the retina, optic
nerve, or retina-calcarine pathways [1]. The striate cortex
shows senile plaques, neurofibrillary tangles and astro-
cytic gliosis [17]. Furthermore, a large amount of
neurofibrillary tangles was found in the peristriate
cortex and infratemporal cortex of AD autopsy tissue
[18–20]. However, a degeneration of large numbers of
optic nerve axons and loss of retinal ganglion cells in AD
patients has been described in several studies [21–24]. A
decreased immunostaining for melatonin-1A (MT1)
receptors in the highly degenerated photoreceptor cell
layer of AD patients has also recently been demonstrated
[25]. Since melatonin is a highly potent antioxidative
substance, our results indicate that in AD patients a lack
of melatonin might be responsible, at least in part, for
the observed degeneration of photoreceptor cells [26].
As the degeneration was not restricted to one specific
cone type this could possibly explain why the acquired
colour vision deficiencies of AD patients observed in the
present study were unspecific and not restricted to a
specific colour axis.
Our study also has limitations that deserve comment.
We assumed that the colour vision tests were appropriate
Table 1. AD patients had significantly more difficulties
with recognising the Ishihara plates No. 5, 9, 10–15 than
controls
Ishihara
plate No. 5 9 10 11 12 13 14 15
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
x2 (df=1) 5.4 8.4 12.5 12.5 12.5 9.4 6.8 6.8
P-value 0.05 0.01 0.0006 0.0006 0.0006 0.005 0.02 0.02
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for ruling out problems due to cognitive decline. Yet the
PV-26 test could only be performed by less than half of
the AD patients, suggesting that even this carefully
chosen test has limitations in application. In spite of
good age matching, the control group differed from the
AD group in visual acuity. Recruiting and testing was not
optimal with regard to duration of test and observer bias.
Nevertheless, we have quite reasonable evidence that
AD patients suffer from an unspecific colour vision
deficiency. Further functional and neuroanatomic studies
are underway to follow up this possibility.
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